Lynx Investment Advisory Vertex Pharmaceuticals Inc Transaction History
Lynx Investment Advisory
- $135 Billion
- Q2 2024
A detailed history of Lynx Investment Advisory transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Lynx Investment Advisory holds 2 shares of VRTX stock, worth $962. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2Holding current value
$962% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding VRTX
# of Institutions
1,707Shares Held
226MCall Options Held
1.2MPut Options Held
1.59M-
Capital World Investors Los Angeles, CA26.7MShares$12.9 Billion2.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA23MShares$11.1 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.3 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.7MShares$5.64 Billion0.24% of portfolio
-
Capital Research Global Investors Los Angeles, CA8.54MShares$4.11 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $124B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...